HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. - Wikidata - awgldk - TriplyDB

HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.

HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.

http://www.wikidata.org/entity/Q37595263

about

The prediction models for postoperative overall survival and disease-free survival in patients with breast cancer Factors associated with the incidence of local recurrences of breast cancer in women who underwent conservative surgery.Interaction between fatty acid synthase and human epidermal growth receptor 2 (HER2) in osteosarcoma cells Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients.Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival.

P2860

Q33891155-8DD8791F-74A6-4FE9-B39F-00A8C7559A8D Q34529914-1E6B9A06-C554-462C-8F0F-A3758A6C92EB Q35038517-25562420-745F-47EC-8B94-393925E07131 Q36729103-E0720546-5C05-472D-969C-722F905AA10B Q37341891-5D905E2E-9A29-41F7-BC3E-74D5934ECD22 Q38262886-99A6C7E6-EC71-40D9-9D7A-CAAC62E7FB13 Q38658647-58BC635D-B45A-44CD-894A-CED7CEFA9EB0 Q40900023-1121D954-2114-403A-915C-AEF4A850921C Q42070603-026E74CB-B00A-4ACF-AA72-E142874C2399 Q53645637-00506E68-CFE1-49FE-900D-2AA72DC50FDD

P2860

HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.

http://www.wikidata.org/entity/Q37595263

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HER2 overexpression a major ri ...... from a French regional cohort.

@en

HER2 overexpression a major ri ...... from a French regional cohort.

@nl

type

label

HER2 overexpression a major ri ...... from a French regional cohort.

@en

HER2 overexpression a major ri ...... from a French regional cohort.

@nl

prefLabel

HER2 overexpression a major ri ...... from a French regional cohort.

@en

HER2 overexpression a major ri ...... from a French regional cohort.

@nl

P1433

Q37595263-6445C517-99AE-475A-BA37-0AA59B1B7021

P1476

Q37595263-5D0C59F9-E66F-4781-BC39-C79AD5CE1BAF

P2093

Q37595263-182F2109-2FB5-4F64-85C8-98C4EF7D8375

Q37595263-2D31BFCF-9CC4-47A7-81A6-3DC55DF586E5

Q37595263-380CCD7A-9BBC-418C-A0CD-987FA38BEF46

Q37595263-71182357-64A3-43F7-94E9-46B8E54909D6

Q37595263-83E36F92-10EE-4631-9B9D-9E876437D46A

Q37595263-8595B48D-1980-472A-B33D-FAA9F314E545

Q37595263-89BC5F61-49FD-4EF6-96A5-A5BA83C05F7E

Q37595263-8A4A14AD-F2EB-4104-83FC-1E2B5C9F966E

Q37595263-AD3CEB00-1699-4D15-9A2B-F1F65CBA9368

Q37595263-BB72939C-E322-45C2-B8B0-FE8252E1BDAD

P2860

Q37595263-074D89B2-57DA-4C8E-94D2-35B1E60BAC6C

Q37595263-08157EA2-C846-4B51-B074-14D2F0BA40E9

Q37595263-0AC0BADB-F58B-43A2-982F-4D611F3DF358

Q37595263-13B14D38-E17A-4186-B7BC-C1294DA58FCE

Q37595263-145F84C9-A4C4-4652-A8D7-D12839460785

Q37595263-1E5EF6BE-A804-44AC-966F-008710B16223

Q37595263-2A088D2D-153E-45EA-BE29-E3F87508B62B

Q37595263-2A0FCDD7-6A07-441A-9A8E-41C5CEBC807C

Q37595263-3D6CED3A-C366-4726-B560-E2B9C3DB9E5E

Q37595263-3FC66853-6991-478D-BF0A-30DBACE9DCEB

P304

Q37595263-BF7F9850-3E10-4431-8672-121D8AA847E5

P31

Q37595263-ECEA9567-730D-411B-8FA8-17044D6C8AD7

P356

Q37595263-43EEAE8F-0993-482D-9E13-8431114CD161

P407

Q37595263-AFD3E072-E866-4EC9-AD72-CCEC0E5C36CC

P433

Q37595263-D5F4062C-60C6-4347-9C41-D7AEB4145C39

P478

Q37595263-BAFDFF14-030C-4306-A7B5-8B31C7310789

P50

Q37595263-20BEE393-CB63-42A4-84B3-42DBDB075A9A

P577

Q37595263-B1F2F8EF-A041-4613-8B5D-E7FF3AE470BC

P5875

Q37595263-F68B5F29-DE8E-4D07-BD2D-AD4DDCCBEBE6

P698

Q37595263-89D9788D-32E8-4613-A152-0D6F2E0508B0

P921

Q37595263-AB06548A-18EB-4620-B2D0-592FB164AAFB

Q37595263-E9A81EA2-EF64-484F-84FD-E79062ECD15C

P932

Q37595263-59FB4502-B6E7-40AB-BEAC-7E6A776B739A

P356

P1433

Cancer Medicine

P1476

HER2 overexpression a major ri ...... from a French regional cohort

@en

P2093

Andre Mathieu

http://www.w3.org/2001/XMLSchema#string

Aurelie Maran-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Emilie Rousseau

http://www.w3.org/2001/XMLSchema#string

Florence Boissiere

http://www.w3.org/2001/XMLSchema#string

Frederic Bibeau

http://www.w3.org/2001/XMLSchema#string

Gilbert Barneon

http://www.w3.org/2001/XMLSchema#string

Gilles Romieu

http://www.w3.org/2001/XMLSchema#string

Jacques Cretin

http://www.w3.org/2001/XMLSchema#string

Jean P Daures

http://www.w3.org/2001/XMLSchema#string

Mireille Granier

http://www.w3.org/2001/XMLSchema#string

P2860

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

Adjuvant trastuzumab in HER2-positive breast cancer.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

P304

134-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.167

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259652359

http://www.w3.org/2001/XMLSchema#string

P698

24407937

http://www.w3.org/2001/XMLSchema#string

P921

P932

3930398

http://www.w3.org/2001/XMLSchema#string